BGMS

Bio Green Med Solution Inc

0.9600

Oct 23 • 3:58 PM ET +0.0162 (1.72%)

0.9502

Aftermarket • 5:00 PM ET -0.0098 (-1.02%)

Industrials Building Products & Equipment Malaysia Nano NASD

Peers: DCM JLHL APT ILAG APG NSSC PPIH MSA CSTE AIRJ

Scroll to Statements

Index	-
Market Cap	6.36M
Enterprise Value	2.57M
Income	-13.31M
Sales	1.86M
Book/sh	1.08
Cash/sh	0.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Apr 29, 2025
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Mar 16, 2004

P/E	-
Forward P/E	-
PEG	-
P/S	3.42
P/B	0.89
P/C	1.68
P/FCF	-
EV/EBITDA	-
EV/Sales	1.38
Quick Ratio	7.22
Current Ratio	8.63
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-3.63
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	90.62% 77.93%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.80%
Sales Y/Y TTM	18510.00%
EPS Q/Q	91.01%
Sales Q/Q	-
Earnings	May 14 AMC
EPS/Sales Surpr.	- -

Insider Own	26.76%
Insider Trans	0.00%
Inst Own	1.55%
Inst Trans	0.94%
ROA	-215.98%
ROE	-245.28%
ROIC	-184.83%
Gross Margin	19.29%
Oper. Margin	-147.13%
Profit Margin	-715.48%
SMA20	6.57%
SMA50	6.52%
SMA200	-1.79%
Trades

Shs Outstand	6.62M
Shs Float	4.85M
Short Float	0.12%
Short Ratio	0.07
Short Interest	0.01M
52W High	2.80 -65.71%
52W Low	0.57 69.49%
Volatility	10.45% 8.42%
ATR (14)	0.09
RSI (14)	54.65
Beta	-0.42
Rel Volume	0.31
Avg Volume	76.30K
Volume	23,819

Perf Week	5.58%
Perf Month	1.59%
Perf Quarter	3.80%
Perf Half Y	-1.10%
Perf YTD	-35.14%
Perf Year	-50.52%
Perf 3Y	-99.96%
Perf 5Y	-99.99%
Perf 10Y	-100.00%
Recom	3.00
Target Price	240.00
Prev Close	0.94
Price	0.96
Change %	1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$17
Apr-27-20	Resumed	ROTH Capital	Buy	$24
Sep-07-18	Initiated	Ladenburg Thalmann	Buy
Oct-16-15	Initiated	H.C. Wainwright	Buy	$5
Feb-04-10	Initiated	Roth Capital	Buy	$7
Oct-28-09	Initiated	Merriman	Buy
Aug-12-08	Initiated	Piper Jaffray	Buy	$5
Mar-12-08	Reiterated	Needham & Co	Buy	$12 → $7
Mar-12-08	Reiterated	Collins Stewart	Buy	$12 → $13
Mar-12-08	Reiterated	Cantor Fitzgerald	Buy	$10.50 → $9
Nov-27-07	Reiterated	Cantor Fitzgerald	Buy	$14 → $10.50
Aug-10-07	Reiterated	Cantor Fitzgerald	Buy	$12 → $14
Jun-04-07	Reiterated	Needham & Co	Buy	$9 → $12
Apr-23-07	Initiated	Lazard Capital	Buy	$11
Apr-10-07	Initiated	Cantor Fitzgerald	Buy	$12

Show Previous Ratings

Sep-29-26 01:52PM	Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-12-26 04:15PM	BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (GlobeNewswire)
Jul-27-26 07:38PM	Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-18-26 11:29AM	Are GBTG, BGMS, SUNE, ESPR Obtaining Fair Deals for their Shareholders? (PR Newswire) -7.24%
Jun-04-26 04:10PM	BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD. (GlobeNewswire) +41.51%
04:15PM	Loading…
May-14-26 04:15PM	BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (GlobeNewswire) -5.14%
Mar-30-26 04:15PM	BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (GlobeNewswire)
Nov-13-25 04:40PM	Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -6.94%
Sep-12-25 06:00AM	Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. (GlobeNewswire) -5.42%
Aug-13-25 04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-25 06:50PM	CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB (GlobeNewswire) -16.31%
Jul-16-25 09:00AM	CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY (GlobeNewswire) -33.50%
Jul-07-25 06:00AM	CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER (GlobeNewswire)
06:00AM	CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT (GlobeNewswire)
Jul-03-25 09:10AM	Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split (TipRanks)
09:00AM	Loading…
Jul-02-25 09:00AM	Cyclacel Pharmaceuticals Announces Stock Split (GlobeNewswire) -26.29%
Jun-20-25 04:30PM	Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock (GlobeNewswire)
Jun-03-25 04:15PM	CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (GlobeNewswire) -13.17%
May-15-25 12:50AM	CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (GlobeNewswire) -5.17%
May-07-25 09:22AM	Cyclacel Pharmaceuticals to implement 1-for-16 reverse stock split; shares fall (Seeking Alpha) -10.14%
09:00AM	CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT (GlobeNewswire)
May-06-25 06:00AM	CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE (GlobeNewswire) +18.43%
Apr-02-25 04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire) -8.85% -6.20%
Mar-24-25 07:30AM	Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock (GlobeNewswire)
Feb-27-25 01:38PM	Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership (GlobeNewswire) +14.92%
Jan-03-25 09:01AM	Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar (GlobeNewswire) +24.02%
Dec-05-24 04:05PM	Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs (GlobeNewswire) -7.37%
Nov-14-24 04:15PM	Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds (GlobeNewswire) -12.60%
Nov-13-24 12:22PM	Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds (GlobeNewswire) +9.76%
Nov-12-24 06:00PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss (Zacks) -8.69%
04:45PM	Loading…
04:45PM	Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 09:15AM	Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule (GlobeNewswire) -17.86%
Oct-23-24 09:15AM	Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium (GlobeNewswire) -25.87%
Oct-09-24 09:15AM	Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium (GlobeNewswire) -9.78%
Sep-25-24 09:15AM	Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study (GlobeNewswire)
Sep-04-24 09:15AM	Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 09:15AM	Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter (GlobeNewswire)
Sep-02-24 09:55AM	Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-14-24 05:35PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.55% -8.97%
04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 09:15AM	Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 12:00PM	Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-26-24 09:15AM	Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions (GlobeNewswire) +19.53%
Jun-06-24 12:00PM	All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy (Zacks) -6.60%
Jun-04-24 08:00AM	Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting (GlobeNewswire)
Jun-03-24 08:00AM	Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential as a Precision Medicine for Cancer (GlobeNewswire) -19.70%
May-15-24 05:01AM	Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) -14.08%
May-14-24 04:05PM	Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire) +11.81%
May-08-24 09:15AM	Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results (GlobeNewswire) +9.95%
May-02-24 04:30PM	Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) -6.04% -19.68%
Apr-30-24 02:37PM	Top Midday Gainers (MT Newswires) +55.88%
07:47AM	Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today? (InvestorPlace)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Apr-01-24 09:15AM	Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer (GlobeNewswire)
Mar-20-24 10:05AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace) -6.37%
04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 04:05PM	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 09:15AM	Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +5.06%
Mar-06-24 09:15AM	Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit (GlobeNewswire) -8.49%
Feb-20-24 09:15AM	Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference (GlobeNewswire)
Jan-30-24 09:15AM	Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-09-24 09:07AM	Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today? (InvestorPlace)
Jan-08-24 09:15AM	Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +28.11%
Jan-02-24 09:15AM	Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-22-23 09:15AM	Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -23.89%
Dec-20-23 10:52AM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2023 (InvestorPlace) -5.34%
10:51AM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q3 2023 (InvestorPlace)
Dec-18-23 09:00AM	Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions (GlobeNewswire)
Dec-12-23 04:05PM	Cyclacel Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -10.99%
Nov-30-23 09:15AM	Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC (GlobeNewswire)
Nov-29-23 12:34PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Nov-28-23 05:15PM	Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
Nov-14-23 10:46AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript (Insider Monkey) -35.54%
Nov-13-23 04:05PM	Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 09:15AM	Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results (GlobeNewswire) -7.42%
Aug-10-23 06:42AM	Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.62%
Aug-03-23 09:15AM	Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 12:00PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why (Zacks)
May-16-23 11:42AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 05:52AM	Q1 2023 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 04:05PM	Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-04-23 09:15AM	Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results (GlobeNewswire) -6.20%
May-03-23 09:15AM	Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit (GlobeNewswire) -11.99%
Mar-08-23 10:45PM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 09:15AM	Cyclacel Pharmaceuticals to Participate in March Investor Conferences (GlobeNewswire)
06:10AM	Q4 2022 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update (GlobeNewswire)
Feb-27-23 09:15AM	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -8.76%
Jan-30-23 09:15AM	Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference (GlobeNewswire)
Jan-05-23 09:15AM	Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 (GlobeNewswire)
Dec-15-22 09:15AM	Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 (GlobeNewswire)
Nov-09-22 04:05PM	Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 10:33AM	Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release (Zacks) +10.53%
Nov-03-22 09:15AM	Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results (GlobeNewswire) -5.00%
Oct-26-22 09:15AM	Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 (GlobeNewswire) +9.02%
Oct-24-22 09:15AM	Cyclacel Hosting Research & Development Day (GlobeNewswire) +6.67%
Oct-13-22 09:15AM	Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yap Kim Choy	10% Owner	Nov 05 '25	Sale	1.70	28,540	48,518	0	Nov 05 06:00 PM
Yap Kim Choy	10% Owner	Oct 30 '25	Sale	1.81	112,260	202,854	28,500	Nov 03 06:00 PM
Kua Khai Loon	10% Owner	Oct 30 '25	Sale	1.80	242,477	436,459	0	Nov 03 06:00 PM
Ong Yee Lung	10% Owner	Oct 30 '25	Sale	1.80	248,814	447,865	0	Nov 03 06:00 PM
Yap Kim Choy	10% Owner	Oct 29 '25	Sale	1.83	110,749	203,114	140,760	Oct 31 06:00 PM
Yap Kim Choy	10% Owner	Oct 28 '25	Sale	1.83	13,111	23,967	251,509	Oct 30 06:00 PM
Yap Kim Choy	10% Owner	Oct 27 '25	Sale	2.12	120,250	254,690	264,620	Oct 29 06:00 PM

Bio Green Med Solution, Inc. which engages in the supply and trading of protective and fire safety equipment to commercial, industrial, healthcare, and residential sectors. Its products include fire extinguishers, foam system, fire-resistant doors, and personal protective equipment. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Kuala Lumpur, Malaysia.

ChairmanDr. Sing Ee Wong

Executive DirectorMr. Cu Seng Kiu

Director of Human ResourcesMs. Gill Christie

Investor Relations ExecutiveGrace Kim

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BGMS

Bio Green Med Solution Inc

Upgrade your Finviz experience